Back to News
Market Impact: 0.2
Remedy Plan Therapeutics Announces Multiple Development and Corporate Milestones as First-In-Class Hyperbolic NAMPT Inhibitor, RPT1G, Advances in Phase 1 Dose Escalation Trial in AML/MDS
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Enrollment has advanced to Cohort 2 in the Phase 1 trial of RPT1G for relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes. The progression indicates continued clinical development, though the article provides no safety, efficacy, enrollment, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- SpaceX will try to put Starship in orbit for the first time on September 22
- A sharp stock market decline could lie around the corner, Wells Fargo warns
- SpaceX’s Starship is finally set for orbit. A lot is riding on its success.
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More
- AI Tools for Family Offices: A Stack by Decision Type